We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos' Affiliate Argenta and Janssen Enter in Integrated Cancer Drug Discovery Service Agreement
News

Galapagos' Affiliate Argenta and Janssen Enter in Integrated Cancer Drug Discovery Service Agreement

Galapagos' Affiliate Argenta and Janssen Enter in Integrated Cancer Drug Discovery Service Agreement
News

Galapagos' Affiliate Argenta and Janssen Enter in Integrated Cancer Drug Discovery Service Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos' Affiliate Argenta and Janssen Enter in Integrated Cancer Drug Discovery Service Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that its affiliate, Argenta Discovery 2009 Limited, has entered into a drug discovery service agreement with Janssen Pharmaceutica N.V. (Janssen), aimed at delivering novel cancer drug candidates. Argenta will provide medicinal chemistry and biology for a number of Janssen oncology targets.

The total contract value for Galapagos for the initial phase of the collaboration could exceed €33.5 M over a five-year period pending the achievement of certain milestones.

This fully integrated drug discovery service agreement calls for Argenta to perform hit-to-lead and lead optimization for a number of Janssen oncology targets, and also activities up to pre-clinical candidate selection. Janssen retains the option to extend the services beyond the initial set of targets, up to a total of 15 targets.

"We are seeing an increased demand for longer term, integrated deals in our services business, which access a variety of our drug discovery capabilities and with Argenta's strong track record of delivering on integrated drug discovery programs, we are well positioned to meet this growing need," said Onno van de Stolpe, CEO of Galapagos.
Advertisement